INVIVYD, INC. Fair Value Adjustment of Warrants
INVIVYD, INC. (IVVD) reported Fair Value Adjustment of Warrants of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Cash Flow
us-gaap:FairValueAdjustmentOfWarrants · last filed 2024-03-28
- INVIVYD, INC. fair value adjustment of warrants for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- INVIVYD, INC. fair value adjustment of warrants for fiscal 2022 was $17.37M.
| Period end | Fair Value Adjustment of Warrants 12 month |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-28 |
| 2022-12-31 | $17.37M 10-K · filed 2024-03-28 |
| 2021-12-31 | $0.00 8-K · filed 2024-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |